Report #2853548

Received Aug 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: WI
Recovered: Recovered
Vaccinated: Apr 12, 2025
Onset: Apr 13, 2025
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	UNK	IM

Symptoms (2)

FatigueNausea

Symptom narrative

Nausea; Fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of nausea in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 12-APR-2025, the patient received the 1st dose of Shingrix (intramuscular). On 13-APR-2025, 1 days after receiving Shingrix, the patient experienced nausea (Verbatim: Nausea) and fatigue (Verbatim: Fatigue). On 16-APR-2025, the outcome of the nausea and fatigue were resolved (duration 3 days). It was unknown if the reporter considered the nausea and fatigue to be related to Shingrix. It was unknown if the company considered the nausea and fatigue to be related to Shingrix. Additional Information: GSK receipt date: 25-JUL-2025 The patient reports that she received her first dose of Shingrix on 12th April 2025 and on the following day experienced nausea and fatigue for two or three days after.